Business Wire

numares and Oxford University sign exclusive license agreement for novel multi-marker diagnostics in multiple sclerosis

Share

Leading NMR diagnostics company numares AG today announced that the company signed an exclusive licence agreement with Oxford University Innovation. This allows numares to translate and exploit preliminary work of Oxford University on Multiple Sclerosis (MS) biomarkers for the development of an urgently needed in-vitro diagnostics (IVD) test able to detect disease progression earlier to improve patient management and outcome. The exclusive licence enables numares to further develop the biomarkers into a multi-marker based diagnostic test and commercialization thereof.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005044/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, is expected to allow evaluation of a multi-marker algorithm for early detection of disease progression in Multiple Sclerosis. Further numares' tests* can be implemented on AXINON®: e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR), and determine risk for cardiovascular disease (CVD). * For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration. (Photo: Business Wire)

In about 85% of patients with MS, the disease initially takes a relapsing-remitting course. Most patients with "relapsing remitting multiple sclerosis (RRMS)" will eventually transition to "secondary progressive multiple sclerosis (SPMS)" with continuous worsening of symptoms. This transition occurs subtly and is difficult to define clinically, requiring retrospective evaluation of the disease course over the past 12 months. This delay in diagnosis prevents timely adoption of treatment regimens for effective patient management and improved long-term clinical outcomes.

The collaboration between Oxford University and numares began in 2017 with the common goal to validate a set of biomarkers, which had been previously identified by Oxford researchers, for detecting transition from RRMS to SPMS. This used clinical data acquired from a multi-centre cohort collected by Oxford’s partners.

numares provided its proprietary AXINON® IVD System that delivers standardized Magnetic Group Signaling (MGS®) measures of metabolite levels in patient samples from Nuclear Magnetic Resonance spectroscopy (NMR). Based on such NMR data, the company develops multi-marker algorithms for several diagnostic tests, by combining relevant biomarkers into "biomarker constellations" and applying machine learning and other modelling approaches.

"We are enthusiastic to enter the next phase of the collaboration and utilize Oxford's excellent preliminary scientific work and numares' expertise for the development of an MS IVD test based on the multi-marker approach," comments Volker Pfahlert, CEO of numares . "Our mission is to improve patient care by providing better diagnostic tools to help physicians better manage their patients. This fruitful collaboration with Oxford researchers gets us closer to our mutual goal to bring first class research to the bedside of MS patients."

Professor Daniel Anthony, Head of Experimental Neuropathology Laboratory, Department of Pharmacology at the University of Oxford and lead scientist on the project, adds:

"We are very pleased to have such an experienced industrial partner in numares to commercialize our research findings as a breakthrough test, which enables early detection of the transition from RRMS stage to SPMS stage for the first time. This will have a significant impact on the care of individuals living with MS. The test opens up the possibility to monitor the condition more closely and thus improve therapeutic decision making."

The IVD development will start in 2022. In early 2021, both parties also agreed to extend their partnership for another two years and expand the approach of multi-marker use in diagnostics to the field of Alzheimer's disease.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail: christiane.proll@numares.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company7.12.2021 14:00:00 EET | Press release

Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”), announced today that they have entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.” Company Overview Alvotech, founded in 2013 in Reykjavik, Iceland, is a vertically integrated platform company focused exclusively on developing and manufacturing biosimilar medicines for the global market. Alvotech has a world class management team of proven and highly experienced pharmaceuticals executives with deep expertise in biologics and biosimilars, led by a visionary founder, Robert Wessman, who has a track record of building g

Vodafone Cook Islands Goes Live With Hansen to Accelerate Digital Transformation Programme7.12.2021 14:00:00 EET | Press release

Hansen Technologies (ASX:HSN) is pleased to announce that Vodafone Cook Islands is now live with Hansen CCB, part of the Hansen Suite for Communications Service Providers (CSPs). Hansen CCB, a tailor-made billing solution leveraging Microsoft Dynamics 365 Business Central, delivers end-to-end ‘Business in a Box’ ERP capability for CSPs around the world. Vodafone now joins Hansen’s family of over 600 global customers. Vodafone Cook Islands was looking to replace its legacy finance and billing systems with a single application, suitable for their direct, local customer base and which could also cater to their relatively large volume of short-term tourist contracts. Being a remote location, the need for a self-managed solution with extensive configuration capability, browser-based interfaces, modern integrations and demonstrated market experience was essential. Hansen CCB allows CSPs to implement and bill new communications services rapidly, and also enables the delivery of fixed and mobi

American Airlines Pilots First to Use CEFA Aviation Flight Replay App in the U.S.7.12.2021 13:16:00 EET | Press release

American Airlines, the world’s largest airline, is the first carrier in the U.S. to adopt CEFA AMS, an Electronic Flight Bag (EFB) application allowing pilots to virtually review flight data on their tablet after landing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005055/en/ CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing. (Photo: Business Wire) CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing. Captain Neil Raaz, Operations Safety Director at American Airlines, says that CEFA AMS is the next step in American’s data-driven approach to relentlessly advance safety. “By choosing CEFA AMS, we are now able to advance the Safety-II approach in a practical way in our operations. This progressive ne

FARO is Taking Care of the Healthcare of Dentists and Patients With the Solar Spectrum LED Technology – SunLike – From Seoul Semiconductor7.12.2021 13:00:00 EET | Press release

From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/ Fig.1 SunLike CRI values for 6500K (Daylight) (Graphic: Business Wire) With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users. FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school. The Eva lamp, compl

Roku Opens Amsterdam Office to Support International Growth7.12.2021 12:00:00 EET | Press release

Roku today announced that it is establishing and investing in an office in the city of Amsterdam. Roku plans to expand its existing presence in The Netherlands to help support its international growth. The Amsterdam office will be located on Weteringschans and offers space for up to 150 employees. Roku is headquartered in Silicon Valley in the United States, in Europe it currently has offices in Denmark, Ukraine and the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005503/en/ Lobby at Roku office in San Jose (Photo: Business Wire) “TV streaming is a global phenomenon, and international growth is a key focus area for us,” said Arthur van Rest, VP International at Roku. “Attracting the right people is crucial to our success, and we believe that The Netherlands has great talent and expertise. We will be looking to hire across various functions, from marketing and business development to finance and legal.

Maria Teresa Hilado to Join Galderma’s Advisory Committee7.12.2021 12:00:00 EET | Press release

Galderma, the world’s largest independent dermatology company, announced today that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022. Ms. Hilado currently serves on the board of directors at Campbell Soup Company, Zimmer Biomet Holdings, Inc. and Pharmaceutical Product Development, LLC. “I look forward to working with Tessa Hilado as we move forward with Galderma’s next growth phase. Her appointment will greatly strengthen the Advisory Committee and shows our dedication to increasing diversity at Galderma.” THOMAS EBELING CHAIRMAN OF THE ADVISORY COMMITTEE, GALDERMA A financial management specialist with over 30 years’ experience, Ms. Hilado brings a proven track record across several global corporations and brands. Her background includes pharmaceuticals, consumer products and industrials. She most recently served as Executive Vice President and Chief Financial Officer at global pharmaceutical company Allergan PLC, from 2014 until her retirement

Longevity Science Foundation Launches Decentralised Blockchain Voting Programme7.12.2021 11:05:00 EET | Press release

The Longevity Science Foundation (LSF) — a Swiss non-profit dedicated to advancing the healthy human lifespan — has announced today it will use blockchain technology in its funding selection process. To do so, the Foundation has created LSF Points, which will be distributed to all Foundation donators. These non-monetary tokens will empower them to vote on which projects and proposals they believe should be funded by the Foundation. All projects under consideration will first be chosen by the LSF Visionary Board for technical soundness, impact, and scientific quality. The executive summary of the programme can be found here. “Beyond having a credible, strict and transparent evaluation and selection process, the LSF wishes to accommodate a system for donors to also express their opinion and vote for their favourites among the applications,” Visionary Board Chairman Evelyne Yehudit Bischof said. “This programme will not only encourage donor involvement but will also help us achieve our mi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom